A detailed history of Nuveen Asset Management, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,671,724 shares of VERV stock, worth $7.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,671,724
Previous 810,497 106.26%
Holding current value
$7.61 Million
Previous $3.96 Million 104.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.4 - $7.86 $3.79 Million - $6.77 Million
861,227 Added 106.26%
1,671,724 $8.09 Million
Q2 2024

Aug 09, 2024

SELL
$4.76 - $12.79 $308,076 - $827,794
-64,722 Reduced 7.39%
810,497 $3.96 Million
Q1 2024

May 13, 2024

BUY
$10.81 - $17.96 $4.51 Million - $7.49 Million
416,971 Added 90.99%
875,219 $11.6 Million
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $2.47 Million - $5.23 Million
279,604 Added 156.51%
458,248 $6.39 Million
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $31,290 - $57,046
2,740 Added 1.56%
178,644 $2.37 Million
Q2 2023

Aug 14, 2023

BUY
$13.34 - $19.9 $202,501 - $302,082
15,180 Added 9.44%
175,904 $3.3 Million
Q1 2023

May 15, 2023

SELL
$14.3 - $24.01 $396,825 - $666,277
-27,750 Reduced 14.72%
160,724 $2.32 Million
Q4 2022

Feb 14, 2023

SELL
$17.85 - $40.7 $1.96 Million - $4.47 Million
-109,910 Reduced 36.84%
188,474 $3.65 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $2.33 Million - $6.18 Million
148,964 Added 99.69%
298,384 $10.3 Million
Q2 2022

Aug 15, 2022

BUY
$11.14 - $23.17 $188,032 - $391,086
16,879 Added 12.73%
149,420 $2.28 Million
Q1 2022

May 16, 2022

BUY
$20.92 - $39.36 $1.6 Million - $3.02 Million
76,644 Added 137.12%
132,541 $2.91 Million
Q4 2021

Feb 14, 2022

SELL
$31.94 - $54.82 $130,954 - $224,762
-4,100 Reduced 6.83%
55,897 $1.83 Million
Q3 2021

Nov 12, 2021

BUY
$46.0 - $73.99 $2.76 Million - $4.44 Million
59,997 New
59,997 $2.82 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.